Evidence map›Paper›PMID 38585631›Full record

ReviewOpen life sciences2024

Exploring antioxidant strategies in the pathogenesis of ALS.

Víctor Pinilla-González, Benjamin Montecinos-Barrientos, Clemente Martin-Kommer, Silvia Chichiarelli, Luciano Saso, Ramón Rodrigo

Abstract readReview
In one paragraph

Review in Open life sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Víctor Pinilla-GonzálezFaculty of Medicine, Institute of Biomedical Sciences, University of Chile, Santiago 8380000, Chile.ORCID https://orcid.org/0000-0001-8308-1624
Benjamin Montecinos-BarrientosFaculty of Medicine, Institute of Biomedical Sciences, University of Chile, Santiago 8380000, Chile.
Clemente Martin-KommerFaculty of Medicine, Institute of Biomedical Sciences, University of Chile, Santiago 8380000, Chile.ORCID https://orcid.org/0009-0000-2331-8079
Silvia ChichiarelliDepartment of Biochemical Sciences "A. Rossi-Fanelli", Sapienza University of Rome, 00185 Rome, Italy.ORCID https://orcid.org/0000-0002-5682-0353
Luciano SasoDepartment of Physiology and Pharmacology "Vittorio Erspamer", Faculty of Pharmacy and Medicine, Sapienza University, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID https://orcid.org/0000-0003-4530-8706
Ramón RodrigoFaculty of Medicine, Institute of Biomedical Sciences, University of Chile, Santiago 8380000, Chile.ORCID https://orcid.org/0000-0003-1724-571X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The central nervous system is essential for maintaining homeostasis and controlling the body's physiological functions. However, its biochemical characteristics make it highly vulnerable to oxidative damage, which is a common factor in neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). ALS is a leading cause of motor neuron disease, characterized by a rapidly progressing and incurable condition. ALS often results in death from respiratory failure within 3-5 years from the onset of the first symptoms, underscoring the urgent need to address this medical challenge. The aim of this study is to present available data supporting the role of oxidative stress in the mechanisms underlying ALS and to discuss potential antioxidant therapies currently in development. These therapies aim to improve the quality of life and life expectancy for patients affected by this devastating disease.

Indexed as

amyotrophic lateral sclerosisantioxidantsiron chelationmultitarget therapyoxidative stress

Identifiers

PMID38585631
PMCPMC10997151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.